Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Amiodarone is a commonly used anti-arrhythmic agent, with well-recognized chronic toxicity. Less well known is amiodarone's potential to cause acute lung damage, which can be severe or, occasionally, life-threatening. Lungs that have already been exposed to physical insults, such as the lungs of patients undergoing cardiac surgery, are particularly susceptible to acute pulmonary toxicity (APT). Unfortunately, cardiac surgery is one of the clinical scenarios in which amiodarone is most commonly used. After reviewing the data, and even in the context of difficulties and discrepancies in the existing literature, we contend that there is sufficient evidence of amiodarone's potentially serious side-effect profile in surgical ICU patients to advise continued caution in its use with this severely ill patient group. We suggest that amiodarone has a potentially important, though underrecognized, role in inducing an APT/ARDS in some patients, such as those undergoing cardiac surgery. We also provide a hypothesis to explain the mechanism by which amiodarone causes lung damage.

Original publication

DOI

10.1378/chest.120.1.275

Type

Journal article

Journal

Chest

Publication Date

07/2001

Volume

120

Pages

275 - 282

Keywords

Acute Disease, Amiodarone, Anti-Arrhythmia Agents, Cardiac Surgical Procedures, Heart, Humans, Intensive Care Units, Lung, Respiratory Distress Syndrome, Adult, Respiratory Insufficiency, Risk Factors